Perspectives on Cannabis as a Substitute for Opioid Analgesics

References

• The National Academies of Sciences, Engineering, and Medicine . The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research . The National Academies Press , Washington, DC, USA ( 2017 ).
   Google Scholar
• Ahrnsbrak R , BoseJ , HeddenS , LipariR , Park-LeeE . Key substance use and mental health indicators in the United States: results from the 2016 National Survey on drug use and health . Subst. Abus. Ment. Heal. Serv. Adm. HHS Publication No. SMA, NSDUH Series H-52 , 17 – 5044 ( 2017 ).
   Google Scholar
• American Society of Addiction Medicine . Opioid addiction. 2016 Facts and Figures . 10 – 12 ( 2016 ). https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdfAccessed on: July-2-2018.
   Google Scholar
• Bachhuber MA , SalonerB , CunninghamCO , BarryCL . Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010 . JAMA Intern. Med.174 ( 10 ), 1668 – 1673 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pardo B . Cannabis policy reforms in the Americas: a comparative analysis of Colorado, Washington, and Uruguay . Int. J. Drug Policy25 ( 4 ), 727 – 735 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Livingston MD , BarnettTE , DelcherC , WagenaarAC . Recreational cannabis legalization and opioid-related deaths in Colorado, 2000–2015 . Am. J. Public Health107 ( 11 ), 1827 – 1829 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Shi Y . Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever . Drug Alcohol Depend.173 , 144 – 150 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Vigil JM , StithSS , AdamsIM , ReeveAP . Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study . PLoS ONE12 ( 11 ), 1 – 13 ( 2017 ).
   Web of Science ®Google Scholar
• Stith SS , VigilJM , AdamsIM , ReeveAP . Effects of legal access to cannabis on scheduled ii–v drug prescriptions . J. Am. Med. Dir. Assoc.19 ( 1 ), 59 – 64.e1 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Sexton M , CuttlerC , FinnellJS , MischleyLK . A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy . Cannabis Cannabinoid Res.1 ( 1 ), 131 – 138 ( 2016 ).
   PubMedGoogle Scholar
• Corroon JM , MischleyLK , SextonM . Cannabis as a substitute for prescription drugs – a cross-sectional study . J. Pain Res.10 , 989 – 998 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Lucas P , WalshZ . Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients . Int. J. Drug Policy.42 , 30 – 35 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Reiman A , WeltyM , SolomonP . Cannabis as a substitute for opioid-based pain medication: patient self-report . Cannabis Cannabinoid Res.2 ( 1 ), 160 – 166 ( 2017 ).
   PubMedGoogle Scholar
• Boehnke KF , LitinasE , ClauwDJ . Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain . J. Pain17 ( 6 ), 739 – 744 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Vyas MB , LeBaronVT , GilsonAM . The use of cannabis in response to the opioid crisis: a review of the literature . Nurs. Outlook.66 ( 1 ), 56 – 65 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime World Drug Report 2017 fact sheet . www.unodc.org/wdr2017/field/WDR17_Fact_sheet.pdf .
   Google Scholar
• Park JY , WuLT . Prevalence, reasons, perceived effects, and correlates of medical marijuana use: a review . Drug Alcohol Depend.177 , 1 – 13 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Hasin DS , SahaTD , KerridgeBTet al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013 . JAMA Psychiatry72 ( 12 ), 1235 – 1242 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Nielsen S , SabioniP , TrigoJMet al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis . Neuropsychopharmacology42 ( 9 ), 1752 – 1765 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Lötsch J , Weyer-MenkhoffI , TegederI . Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings . Eur. J. Pain22 ( 3 ), 471 – 484 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Lucas P . Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain . J. Psychoactive Drugs44 ( 2 ), 125 – 133 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lu Y , AndersonHD . Cannabinoid signaling in health and disease . Can. J. Physiol. Pharmacol.95 ( 4 ), 311 – 327 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Russo E , GuyGW . A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol . Med. Hypotheses.66 ( 2 ), 234 – 246 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Romero-Sandoval EA , FinchamJE , KolanoAL , SharpeB , Alvarado-VázquezPA . Cannabis for chronic pain: challenges and considerations . Pharmacother. J. Hum. Pharmacol. Drug Ther.38 ( 6 ), 651 – 662 ( 2018 ).
   Google Scholar
• Hampson AJ , GrimaldiM , LolicM , WinkD , RosenthalR , AxelrodJ . Neuroprotective antioxidants from marijuana . Ann. N. Y. Acad. Sci.899 , 274 – 282 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Maroon J , BostJ . Review of the neurological benefits of phytocannabinoids . Surg. Neurol. Int.9 , 91 ( 2018 ).
   PubMedGoogle Scholar
• Burstein S . Cannabidiol (CBD) and its analogs: a review of their effects on inflammation . Bioorganic Med. Chem.23 ( 7 ), 1377 – 1385 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Grill M , HasenoehrlC , KienzlM , KarglJK , SchichoR . Cellular localization and regulation of receptors and enzymes of the endocannabinoid system in intestinal and systemic inflammation . Histochem. Cell Biol.151 ( 1 ), 5 – 20 ( 2019 ).
   PubMed Web of Science ®Google Scholar
• Uranga JA , VeraG , AbaloR . Cannabinoid pharmacology and therapy in gut disorders . Biochem. Pharmacol. ( 5 ), pii: S0006-2952(18)30318-6 ( 2018 ) ( Epub ahead of print ).
   PubMedGoogle Scholar
• Schicho R , StorrM . Cannabis finds its way into treatment of Crohn’s disease . Pharmacology93 ( 1–2 ), 1 – 3 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Woodhams SG , ChapmanV , FinnDP , HohmannAG , NeugebauerV . The cannabinoid system and pain . Neuropharmacology124 , 105 – 120 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Cichewicz DL . Synergistic interactions between cannabinoid and opioid analgesics . Life Sci.74 ( 11 ), 1317 – 1324 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Viganò D , RubinoT , ParolaroD . Molecular and cellular basis of cannabinoid and opioid interactions . Pharmacol. Biochem. Behav.81 ( 2 ), 360 – 368 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Howlett AC . International union of pharmacology. XXVII. Classification of cannabinoid receptors . Pharmacol. Rev.54 ( 2 ), 161 – 202 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Hohmann AG , BrileyEM , HerkenhamM . Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord . Brain Res.822 ( 1–2 ), 17 – 25 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Salio C , FischerJ , FranzoniMFet al. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn . Neuroreport.12 ( 17 ), 3689 – 3692 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Price DD . Psychological and neural mechanisms of the affective dimension of pain . Science9 ( 5472 ), 1769 – 1772 ( 2000 ).
   Google Scholar
• Ibrahim MM , PorrecaF , LaiJet al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids . Proc. Natl Acad. Sci.102 ( 8 ), 3093 – 3098 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Pugh G , SmithPB , DombrowskiDS , WelchSP . The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord . J. Pharmacol. Exp. Ther.279 ( 2 ), 608 – 616 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Cooper ZD , BediG , RameshD , BalterR , ComerSD , HaneyM . Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability . Neuropsychopharmacology43 ( 10 ), 2046 – 2055 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Caputi TL , HumphreysK . Medical marijuana users are more likely to use prescription drugs medically and nonmedically . J. Addict. Med.12 ( 14 ), 295 – 299 ( 2018 ).
   PubMedGoogle Scholar
• Olfson M , WallMM , LiuS-M , BlancoC . Cannabis use and risk of prescription opioid use disorder in the United States . Am. J. Psychiatry175 ( 1 ), 47 – 53 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Nugent SM , YarboroughBJ , SmithNXet al. Patterns and correlates of medical cannabis use for pain among patients prescribed long-term opioid therapy . Gen. Hosp. Psychiatry50 , 104 – 110 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Franklyn AM , EiblJK , GauthierGJ , MarshDC . The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada . PLoS ONE12 ( 11 ), 1 – 11 ( 2017 ).
   Web of Science ®Google Scholar
• Nugent SM , MorascoBJ , O’NeilMEet al. The effects of cannabis among adults with chronic pain and an overview of general harms a systematic review . Ann. Intern. Med.167 ( 5 ), 319 – 331 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Mücke M , PhillipsT , RadbruchL , PetzkeF , HäuserW . Cannabis-based medicines for chronic neuropathic pain in adults . Cochrane Database Syst. Rev. ( 3 ), CD012182 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Davis MP . Cancer-related neuropathic pain: review and selective topics . Hematol. Oncol. Clin. North Am.32 , 417 – 431 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Aviram J , Samuelly-LeichtagG . Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials . Pain Physician20 ( 6 ), E755 – E796 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Lichtman AH , LuxEA , McQuadeRet al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as a adjunctive therapy in advanced cancer patients with chronic uncontrolled pain . J. Pain Symptom Manage.55 ( 2 ), 179 – 188.e1 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Castelli L , ProsperiniL , PozzilliC . Balance worsening associated with nabiximols in multiple sclerosis . Mult. Scler. J.1 , 1 – 5 ( 2018 ).
   Google Scholar
• Häuser W , PetzkeF , FitzcharlesMA . Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management – an overview of systematic reviews . Eur. J. Pain22 ( 3 ), 455 – 470 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Finney JW , HumphreysK , HarrisAH . What ecologic analyses cannot tell us about medical marijuana legalization and opioid pain medication mortality . JAMA Intern Med.175 ( 4 ), 655 – 656 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Greenland S . A review of multilevel theory for ecologic analyses . Stat. Med.21 ( 3 ), 389 – 395 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Robinson WS . Ecological correlations and the behavior of individuals . Am. Sociol. Rev.15 ( 3 ), 351 ( 1950 ).
   Web of Science ®Google Scholar
• Caputi TL , SabetKA , LivingstonMD . AJPH Letters and Responses . AJPH Lett. Responses108 ( 3 ), e12 – e13 ( 2018 ).
   PubMedGoogle Scholar
• Theriault BM , SchlesingerJJ . Potential impact of medical marijuana on nonmedical opioid use . Am. J. Psychiatry175 ( 3 ), 284 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Roy-Byrne P , MaynardC , BumgardnerKet al. Are medical marijuana users different from recreational users? The view from primary care . Am. J. Addict.24 ( 7 ), 599 – 606 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hanson K . State medical marijuana laws . Natl. Conf. State Legis.www.ncsl.org/research/health/state-medical-marijuana-laws.aspx .
   Google Scholar
• Klieger SB , GutmanA , AllenL , PaculaRL , IbrahimJK , BurrisS . Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017 . Addiction112 ( 12 ), 2206 – 2216 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Huestis MA . Human cannabinoid pharmacokinetics . Chem. Biodivers.4 ( 8 ), 1770 – 1804 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Romero-Sandoval EA , KolanoAL , Alvarado-VázquezPA . Cannabis and cannabinoids for chronic pain . Curr. Rheumatol. Rep.19 ( 11 ), 67 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Agurell S , HalldinM , LindgrenJEet al. Pharmacokinetics and metabolism of delta-tetrahydrocannabinol and other cannabinoids with emphasis on man . Pharmacol. Rev.38 ( 1 ), 21 – 43 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Budney AJ , SargentJD , LeeDC . Vaping cannabis (marijuana): parallel concerns to e-cigs?Addiction110 ( 11 ), 1699 – 1704 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Newmeyer MN , SwortwoodMJ , AbulseoudOA , HuestisMA . Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration . Drug Alcohol Depend.175 , 67 – 76 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Issa MA , NarangS , JamisonRNet al. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain . Clin. J. Pain30 ( 6 ), 472 – 478 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Szaflarski JP , BebinEM , CutterGet al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study . Epilepsy Behav.87131 – 136 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Ohlsson A , LindgrenJE , WahlenA , AgurellS , HollisterLE , GillespieHK . Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking . Clin. Pharmacol. Ther.28 ( 3 ), 409 – 416 ( 1980 ).
   PubMed Web of Science ®Google Scholar
• Chatkin JM , ZabertG , ZabertIet al. Lung disease associated with marijuana use . Arch. Bronconeumol. (English Ed.).53 ( 99 ), 510 – 515 ( 2017 ).
   PubMedGoogle Scholar
• Knapp AA , LeeDC , BorodovskyJT , AutySG , GabrielliJ , BudneyAJ . Emerging trends in cannabis administration among adolescent cannabis users . J. Adolesc. Heal. doi:10.1016/j.jadohealth.2018.07.012 ( 2018 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Ellis RJ , ToperoffW , VaidaFet al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial . Neuropsychopharmacology34 ( 3 ), 672 – 680 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ware MA , WangT , ShapiroSet al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial . CMAJ182 ( 14 ), E694 – E701 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wilsey B , MarcotteT , TsodikovAet al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain . J. Pain9 ( 6 ), 506 – 521 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Wallace MS , MarcotteTD , UmlaufA , GouauxB , AtkinsonJH . Efficacy of inhaled cannabis on painful diabetic neuropathy . J. Pain16 ( 7 ), 616 – 627 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wilsey B , MarcotteT , DeutschR , GouauxB , SakaiS , DonagheH . Low-dose vaporized cannabis significantly improves neuropathic pain . J. Pain14 ( 2 ), 136 – 148 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wilsey B , MarcotteTD , DeutschR , ZhaoH , PrasadH , PhanA . An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease . J. Pain17 ( 9 ), 982 – 1000 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Colizzi M , BhattacharyyaS . Cannabis use and the development of tolerance: a systematic review of human evidence . Neurosci. Biobehav. Rev.93 , 1 – 25 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Hunault CC , BöckerKBE , StellatoRK , KenemansJL , De VriesI , MeulenbeltJ . Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: A randomized, crossover clinical trial . Psychopharmacology (Berl.)231 ( 24 ), 4723 – 4733 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Childs E , LutzJA , de WitH . Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress . Drug Alcohol Depend.177 , 136 – 144 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Curran VH , BrignellC , FletcherS , MiddletonP , HenryJ . Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users . Psychopharmacology (Berl.)164 ( 1 ), 61 – 70 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Bedi G , CooperZD , HaneyM . Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers . Addict. Biol.18 ( 5 ), 872 – 881 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Clark WC , JanalMN , ZeidenbergP , NahasGG . Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis . J. Clin. Pharmacol.21 ( S1 ), 299S – 310S ( 1981 ).
   PubMedGoogle Scholar
• Wallace M , SchulteisG , AtkinsonJHet al. VI Pain and regional anesthesia dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers . Anesthesiology107 ( 5 ), 785 – 796 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ramaekers JG , TheunissenEL , De BrouwerM , ToennesSW , MoellerMR , KauertG . Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users . Psychopharmacology (Berl.)214 ( 2 ), 391 – 401 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lindsey WT , StewartD , ChildressD . Drug interactions between common illicit drugs and prescription therapies . Am. J. Drug Alcohol Abuse38 ( 4 ), 334 – 343 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mahvan TD , HilaireML , MannAet al. Marijuana use in the elderly: implications and considerations . Consult Pharm.32 ( 6 ), 341 – 351 ( 2017 ).
   PubMedGoogle Scholar
• Anderson GD , ChanLN . Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products . Clin. Pharmacokinet.55 ( 11 ), 1353 – 1368 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Starzer MSK , NordentoftM , Hjorth⊘jC . Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis . Am. J. Psychiatry175 ( 4 ), 343 – 350 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Arseneault L , CannonM , PoultonRet al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study drug points . BMJ325 , 1212 – 1213 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Degenhardt L , HallW , LynskeyM . Testing hypotheses about the relationship between cannabis use and psychosis . Drug Alcohol Depend.71 ( 1 ), 37 – 48 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Di Forti M , MarconiA , CarraEet al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study . Lancet Psychiatry2 ( 3 ), 233 – 238 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Andréasson S , EngströmA , AllebeckP , RydbergU . Cannabis and schizophrenia a longitudinal study of Swedish conscripts . Lancet330 ( 8574 ), 1483 – 1486 ( 1987 ).
   Web of Science ®Google Scholar
• Alon MH , Saint-FleurMO . Synthetic cannabinoid induced acute respiratory depression: case series and literature review . Respir. Med. Case Reports22 , 137 – 141 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Yamanoglu A , Celebi YamanogluNG , EvranT , SogutO . How much can synthetic cannabinoid damage the heart? A case of cardiogenic shock following resistant ventricular fibrillation after synthetic cannabinoid use . J. Clin. Ultrasound.1 – 5 ( 2018 ).
   Web of Science ®Google Scholar
• Law R , SchierJ , MartinCet al. Notes from the field . Morb. Mortal. Wkly Rep.64 ( 22 ), 1 – 9 ( 2012 ).
   Google Scholar
• Hall W , DegenhardtL . Adverse health effects of non-medical cannabis use . Lancet374 ( 9698 ), 1383 – 1391 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lopez-Quintero C , Pérez de los CobosJ , HasinDSet al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) . Drug Alcohol Depend.115 ( 1–2 ), 120 – 130 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Brown MRD , Farquhar-SmithWP . Cannabinoids and cancer pain: a new hope or a false dawn?Eur. J. Intern. Med.30 – 36 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Bajic D , MonoryK , ConradAet al. Cannabinoid receptor type 1 in the brain regulates the affective component of visceral pain in mice . Neuroscience384 , 397 – 405 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Kazantzis NP , CaseySL , SeowPW , MitchellVA , VaughanCW . Opioid and cannabinoid synergy in a mouse neuropathic pain model . Br. J. Pharmacol.2521 – 2531 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Grenald SA , YoungMA , WangYet al. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists . Neuropharmacology116 , 59 – 70 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Maguire DR , FranceCP . Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio . Eur. J. Pharmacol.819 ( 11 ), 217 – 224 ( 2018 ).
   PubMedGoogle Scholar
• Zhang M , DongL , ZouHet al. Effects of cannabinoid type 2 receptor agonist AM1241 on morphine-induced antinociception, acute and chronic tolerance, and dependence in mice . J. Pain19 ( 10 ), 1113 – 1129 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Lin X , DhopeshwarkarAS , HuibregtseM , MackieK , HohmannAG . The slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence . Mol. Pharmacol.93 ( 2 ), 49 – 62 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Maguire DR , FranceCP . Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure . Psychopharmacology (Berl.)235 , 2357 – 2365 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Weed PF , GerakLR , FranceCP . Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys . Eur. J. Pharmacol.833 ( May ), 94 – 99 ( 2018 ).
   PubMedGoogle Scholar
• Han S , ThoresenL , JungJ-Ket al. Discovery of APD371: identification of a highly potent and selective cb 2 agonist for the treatment of chronic pain . ACS Med. Chem. Lett.8 ( 12 ), 1309 – 1313 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Arena Pharmaceuticals to present Phase I and preclinical data on APD371 in development for treatment of pain associated with Crohn’s disease at American Pain Society Annual Scientific Summit . PR Newswire ( 2018 ). www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-phase-1-and-preclinical-data-on-apd371-in-development-for-treatment-of-pain-associated-with-crohns-disease-at-american-pain-society-annual-scientific-summit-300606279.html .
   Google Scholar
• Olorinab (APD371) . Arena Pharmaceuticals . www.arenapharm.com/pipeline/apd371/ .
   Google Scholar
• Grof CPL . Cannabis, from plant to pill . Br. J. Clin. Pharmacol.1 – 5 ( 2018 ).
   Web of Science ®Google Scholar
• Calvi L , PentimalliD , PanseriSet al. Comprehensive quality evaluation of medical Cannabis sativa L. inflorescence and macerated oils based on HS-SPME coupled to GC–MS and LC-HRMS (q-exactive orbitrap®) approach . J. Pharm. Biomed. Anal.150 , 208 – 219 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• MacCallum CA , RussoEB . Practical considerations in medical cannabis administration and dosing . Eur. J. Intern. Med.49 , 12 – 19 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Russo EB . Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects . Br. J. Pharmacol.163 ( 7 ), 1344 – 1364 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Blasco-Benito S , Seijo-VilaM , Caro-VillalobosMet al. Appraising the “entourage effect”: antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer . Biochem. Pharmacol.157 , 285 – 293 ( 2011 ).
   Google Scholar
• Sanchez-Ramos J . The entourage effect of the phytocannabinoids . Ann. Neurol.77 ( 6 ), 1083 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Peres FF , LimaAC , HallakJEC , CrippaJA , SilvaRH , AbílioVC . Cannabidiol as a promising strategy to treat and prevent movement disorders?Front. Pharmacol.9 ( 5 ), 1 – 12 ( 2018 ).
   PubMedGoogle Scholar
• Patrice A , HarrisMD . AMA sees progress in declining opioid prescriptions . American Medical Association ( 2018 ). www.ama-assn.org/ama-sees-progress-declining-opioid-prescriptions .
   Google Scholar